John L. Higgins - Apr 28, 2023 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed
Stock symbol
TECH
Transactions as of
Apr 28, 2023
Transactions value $
-$35
Form type
4
Date filed
5/2/2023, 04:49 PM
Previous filing
Feb 1, 2023
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $350K +16K +68.49% $21.85 39.4K Apr 28, 2023 Direct
transaction TECH Common Stock Tax liability -$350K -4.38K -11.12% $79.88 35K Apr 28, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -16K -100% $0.00* 0 Apr 28, 2023 Common Stock 16K $21.85 Direct
holding TECH Stock Options (Right to Buy) 16K Apr 28, 2023 Common Stock 16K $22.95 Direct
holding TECH Stock Options (Right to Buy) 17K Apr 28, 2023 Common Stock 17K $21.84 Direct
holding TECH Stock Options (Right to Buy) 15.9K Apr 28, 2023 Common Stock 15.9K $25.30 Direct
holding TECH Stock Options (Right to Buy) 12.5K Apr 28, 2023 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K Apr 28, 2023 Common Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K Apr 28, 2023 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K Apr 28, 2023 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K Apr 28, 2023 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K Apr 28, 2023 Common Stock 3.46K $73.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests on the earlier of the one year anniversary of the grant date (10/27/22) or the date of Bio-Techne's 2023 annual meeting of shareholders.

Remarks:

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.